Drug Search Results
More Filters [+]

Letaxaban

Alternative Names: letaxaban, tak-442, tak442, tak 442
Latest Update: 2016-04-13
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: FXa Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Letaxaban

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Acute Coronary Syndrome|Thrombosis|Venous Thromboembolism

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

TAK-442_202

P2

Completed

Acute Coronary Syndrome

2010-06-01

2008-000091-24

P2

Completed

Acute Coronary Syndrome

2009-06-26

TAK-442_201

P2

Completed

Venous Thromboembolism

2008-10-01

JapicCTI-090865

P2

Completed

Thrombosis

None

Recent News Events

Date

Type

Title